Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.53 |
| ▸ | SHBG | P04278 | 5/20 | 0.53 |
| ▸ | STS | P08842 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | PGR | P06401 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.53 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.53 |
| ▸ | SNCA | P37840 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959369 | 1.00 | ESR1 (0.53) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL29500480 | 1.00 | ESR1 (0.53) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL8938727 | 0.95 | SHBG (0.50) | ESR1ESR2SHBGSTSHSD17B10 | |
| Benzoic Acid SCHEMBL9628348 | 0.89 | STS (0.47) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL9627672 | 0.85 | LMNA (0.55) | ESR1ESR2STSHSD17B10LMNA | |
| SCHEMBL8959365 | 0.83 | ESR1 (0.52) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL8959381 | 0.83 | ESR1 (0.52) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL9146993 | 0.83 | ESR1 (0.52) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL259537 | 0.83 | ESR1 (0.52) | ESR1ESR2SHBGSTSHSD17B10 | |
| SCHEMBL9725182 | 0.82 | ESR1 (0.48) | ESR1ESR2SHBGSTSHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655916-B1 | TRANSDERMAL APPLICATION AGENT CONTAINING 3-KETO-DESOGESTREL | SCHERING AG (DE) | 1998-02-04 | — | — | EP | claimed |
| EP-0318490-B1 | 14,17-G(B)-ETHANO-14-G(B)-ESTRATRIENES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | claimed |
| US-4789671-A | ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-12-06 | — | — | US | claimed |
| US-9132101-B2 | Administration form based on cross-linked hydrophilic polymers | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20130225542-A1 | Therapeutic Gestagens For The Treatment Of Premenstrual Dysphoric Disorder | SCHERING AKITIENGESELLSCHAFT (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20120225853-A1 | HORMONE REPLACEMENT THERAPY AND DEPRESSION | Bayer Pharma AG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120028935-A1 | Therapeutic Gestagens for the Treatment of Premenstrual Dysphoric Disorder | FOEGH MARIE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20090137537-A1 | THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER | FOEGH MARIE | 2009-05-28 | — | — | US | disclosed |
| EP-1635843-B1 | THERAPY COMPRISING DIENOGEST FOR HORMONE REPLACEMENT AND DEPRESSION | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20070111974-A1 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070071796-A1 | Administration form based on cross-linked hydrophilic polymers | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-0664811-B1 | GESTAGENICALLY ACTIVE 19,11-BRIDGED 4-ESTRENES | SCHERING AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0513947-B1 | 14 Alpha, 16alpha-ethano- and 14alpha, 16alpha ethenoestratrienes | SCHERING AG (DE) | 1995-11-15 | — | — | EP | disclosed |
| US-5439902-A | Estrogen therapy, birth control | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0513947-A1 | 14 Alpha, 16alpha-ethano- and 14alpha, 16alpha ethenoestratrienes | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992019641-A1 | 14α,16α-ETHANO AND 14α,16α-ETHENO ESTRATRIENES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-11-12 | — | — | WO | disclosed |
| US-5134136-A | Estrogenic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-07-28 | — | — | US | disclosed |
| EP-0318490-B1 | 14,17-G(B)-ETHANO-14-G(B)-ESTRATRIENES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
| EP-0372665-A1 | 14-Alpha, 17-alpha-ethane estratrienes | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-06-13 | — | — | EP | disclosed |
| US-4789671-A | ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-12-06 | — | — | US | disclosed |